Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis, such as the COVID-19 pandemic

• DOI: 10.3332/ecancer.2020.1027
• Publication Date: 2020-04-27T16:35:31Z
• Authors: Covadonga Marti; José I Sánchez-Mé...
• Keywords: luminal; 03 medical and health sciences; breast cancer; 0302 clinical medicine; Medicina; endocrine therapy; neoadjuvant; Short Communication; COVID-19; 3. Good health

The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care.